

Emmanuel Scotet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1442340/publications.pdf>

Version: 2024-02-01

72
papers

4,943
citations

94433

37
h-index

95266

68
g-index

72
all docs

72
docs citations

72
times ranked

5048
citing authors

#	ARTICLE	IF	CITATIONS
1	Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human $\hat{3}\hat{1}$ T-cell subset. <i>Blood</i> , 2012, 120, 2269-2279.	1.4	443
2	The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human $\hat{3}\hat{9}\hat{V}\hat{2}$ T Cells. <i>Immunity</i> , 2014, 40, 490-500.	14.3	375
3	Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10685-10690.	7.1	348
4	Tumor Recognition following $\hat{3}\hat{9}\hat{V}\hat{2}$ T Cell Receptor Interactions with a Surface F1-ATPase-Related Structure and Apolipoprotein A-I. <i>Immunity</i> , 2005, 22, 71-80.	14.3	268
5	$\hat{3}\hat{9}\hat{V}\hat{2}$ T Cell Response to Colon Carcinoma Cells. <i>Journal of Immunology</i> , 2005, 175, 5481-5488.	0.8	197
6	Human $\hat{3}\hat{9}\hat{V}\hat{2}$ T cells: promising new leads for immunotherapy of infections and tumors. <i>Current Opinion in Immunology</i> , 2006, 18, 539-546.	5.5	189
7	The interplay between the duration of TCR and cytokine signaling determines T cell polarization. <i>European Journal of Immunology</i> , 1999, 29, 4092-4101.	2.9	169
8	T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis.. <i>Journal of Experimental Medicine</i> , 1996, 184, 1791-1800.	8.5	160
9	The Molecular Basis for Modulation of Human $\hat{3}\hat{9}\hat{V}\hat{2}$ T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific Antibodies. <i>Journal of Biological Chemistry</i> , 2012, 287, 32780-32790.	3.4	139
10	CXCR5 Identifies a Subset of $\hat{3}\hat{9}\hat{V}\hat{2}$ T Cells which Secrete IL-4 and IL-10 and Help B Cells for Antibody Production. <i>Journal of Immunology</i> , 2006, 177, 5290-5295.	0.8	133
11	Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes. <i>European Journal of Immunology</i> , 1999, 29, 973-985.	2.9	130
12	Cutting Edge: CD1d Restriction and Th1/Th2/Th17 Cytokine Secretion by Human $\hat{3}$ T Cells. <i>Journal of Immunology</i> , 2013, 191, 30-34.	0.8	130
13	Potential of Antigen-Stimulated $\hat{3}\hat{9}\hat{V}\hat{2}$ T Cell Cytokine Production by Immature Dendritic Cells (DC) and Reciprocal Effect on DC Maturation. <i>Journal of Immunology</i> , 2006, 176, 1386-1393.	0.8	127
14	Self/non-self discrimination by human $\hat{3}\hat{1}$ T cells: simple solutions for a complex issue?. <i>Immunological Reviews</i> , 2007, 215, 123-135.	6.0	121
15	RhoB Mediates Phosphoantigen Recognition by $\hat{3}\hat{9}\hat{V}\hat{2}$ T Cell Receptor. <i>Cell Reports</i> , 2016, 15, 1973-1985.	6.4	112
16	Sensing of cell stress by human $\hat{3}\hat{1}$ TCR-dependent recognition of annexin A2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3163-3168.	7.1	97
17	Epstein-Barr virus and rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2004, 3, 362-367.	5.8	94
18	A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. <i>European Journal of Immunology</i> , 2000, 30, 2531-2539.	2.9	84

#	ARTICLE	IF	CITATIONS
19	NKG2D Costimulates Human $\text{V}\alpha\text{2}$ T Cell Antitumor Cytotoxicity through Protein Kinase C δ -Dependent Modulation of Early TCR-Induced Calcium and Transduction Signals. <i>Journal of Immunology</i> , 2010, 185, 55-63.	0.8	84
20	Regulation of Inhibitory and Activating Killer-Cell Ig-Like Receptor Expression Occurs in T Cells After Termination of TCR Rearrangements. <i>Journal of Immunology</i> , 2001, 166, 2487-2494.	0.8	78
21	Early Triggering of Exclusive IFN- γ Responses of Human $\text{V}\alpha\text{2}$ T Cells by TLR-Activated Myeloid and Plasmacytoid Dendritic Cells. <i>Journal of Immunology</i> , 2009, 183, 3625-3633.	0.8	71
22	Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. <i>Blood</i> , 2004, 103, 1408-1416.	1.4	69
23	Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity. <i>Clinical Cancer Research</i> , 2017, 23, 6292-6304.	7.0	69
24	IL-21-Mediated Potentiation of Antitumor Cytolytic and Proinflammatory Responses of Human $\text{V}\alpha\text{2}$ T Cells for Adoptive Immunotherapy. <i>Journal of Immunology</i> , 2009, 182, 3423-3431.	0.8	61
25	Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. <i>Cell Death and Disease</i> , 2020, 11, 19.	6.3	53
26	Repeated Systemic Administrations of Both Aminobisphosphonates and Human $\text{V}\alpha\text{2}$ T Cells Efficiently Control Tumor Development In Vivo. <i>Journal of Immunology</i> , 2013, 191, 1993-2000.	0.8	51
27	Synergistic targeting of breast cancer stem-like cells by human $\text{V}\beta\text{1}$ T cells and CD8 ⁺ T cells. <i>Immunology and Cell Biology</i> , 2017, 95, 620-629.	2.3	51
28	Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. <i>European Journal of Immunology</i> , 2002, 32, 3102-3107.	2.9	50
29	Bridging innate and adaptive immunity through gd T - dendritic cell crosstalk. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 6872.	3.0	49
30	$\text{V}\alpha\text{2}$ T cell diversity and the receptor interface with tumor cells. <i>Journal of Clinical Investigation</i> , 2020, 130, 4637-4651.	8.2	49
31	Development of ICT01, a first-in-class, anti-BTN3A antibody for activating $\text{V}\alpha\text{2}$ T cell-mediated antitumor immune response. <i>Science Translational Medicine</i> , 2021, 13, eabj0835.	12.4	49
32	CD4 engagement by CD1d potentiates activation of CD4 ⁺ invariant NKT cells. <i>Blood</i> , 2007, 110, 251-258.	1.4	47
33	Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates $\text{V}\alpha\text{2}$ TCR clonotypes and interferes with phosphoantigen activation. <i>European Journal of Immunology</i> , 2017, 47, 982-992.	2.9	47
34	+1 Frameshifting as a Novel Mechanism to Generate a Cryptic Cytotoxic T Lymphocyte Epitope Derived from Human Interleukin 10. <i>Journal of Experimental Medicine</i> , 2002, 195, 353-358.	8.5	46
35	Molecules and Mechanisms Implicated in the Peculiar Antigenic Activation Process of Human $\text{V}\alpha\text{2}$ T Cells. <i>Frontiers in Immunology</i> , 2015, 5, 657.	4.8	46
36	BTN3A molecules considerably improve $\text{V}\alpha\text{2}$ T cells-based immunotherapy in acute myeloid leukemia. <i>Oncot Immunology</i> , 2016, 5, e1146843.	4.6	46

#	ARTICLE	IF	CITATIONS
37	Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. <i>Oncotarget</i> , 2018, 9, 11451-11464.	1.8	46
38	Human V β 9V α 2 T cells: From signals to functions. <i>Seminars in Immunology</i> , 2010, 22, 199-206.	5.6	45
39	BTN2A1, an immune checkpoint targeting V β 9V α 2 T cell cytotoxicity against malignant cells. <i>Cell Reports</i> , 2021, 36, 109359.	6.4	44
40	The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1995, 1264, 238-242.	2.4	42
41	Stereotaxic administrations of allogeneic human V β 9V α 2 T cells efficiently control the development of human glioblastoma brain tumors. <i>Oncolmmunology</i> , 2016, 5, e1168554.	4.6	36
42	The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human V β 9V α 2 T Cells. <i>Journal of Immunology</i> , 2017, 198, 4228-4234.	0.8	36
43	Molecular regulation of CC-chemokine receptor 3 expression in human T helper 2 cells. <i>Blood</i> , 2001, 98, 2568-2570.	1.4	31
44	NKG2D Controls Natural Reactivity of V β 9V α 2 T Lymphocytes against Mesenchymal Glioblastoma Cells. <i>Clinical Cancer Research</i> , 2019, 25, 7218-7228.	7.0	28
45	Towards Deciphering the Hidden Mechanisms That Contribute to the Antigenic Activation Process of Human V β 9V α 2 T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 828.	4.8	27
46	Exon III splicing switch of fibroblast growth factor (FGF) receptor-2 and -3 can be induced by FGF-1 or FGF-2. <i>Oncogene</i> , 1998, 17, 67-76.	5.9	26
47	Overexpression of vascular endothelial growth factor induces cell transformation in cooperation with fibroblast growth factor 2. <i>Oncogene</i> , 1997, 14, 463-471.	5.9	22
48	Modulation of inflammation through IL-17 production by $\gamma\delta$ T cells: Mandatory in the mouse, dispensable in humans?. <i>Immunology Letters</i> , 2009, 127, 8-12.	2.5	21
49	Up-regulation of cytolytic functions of human V α 2 β 9 V α 2 T lymphocytes through engagement of ILT2 expressed by tumor target cells. <i>Blood</i> , 2011, 117, 2864-2873.	1.4	21
50	Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes. , 2020, 8, e000311.		20
51	Frequent recognition of BCRF1, a late lytic cycle protein of Epstein-Barr virus, in the HLA-B*2705 context: evidence for a TAP-independent processing. <i>European Journal of Immunology</i> , 2001, 31, 708-715.	2.9	19
52	CD1d-Restricted Antigen Presentation by V β 9V α 2-T Cells Requires Trogocytosis. <i>Cancer Immunology Research</i> , 2014, 2, 732-740.	3.4	19
53	Activated iNKT cells promote V β 9V α 2-T cell anti-tumor effector functions through the production of TNF- α . <i>Clinical Immunology</i> , 2012, 142, 194-200.	3.2	16
54	Immunodominant CD8 α T cell response to Epstein-Barr virus. <i>Biomedicine and Pharmacotherapy</i> , 2001, 55, 373-380.	5.6	15

#	ARTICLE	IF	CITATIONS
55	IL-21 Increases the Reactivity of Allogeneic Human V β 9V α 2 T Cells Against Primary Glioblastoma Tumors. <i>Journal of Immunotherapy</i> , 2018, 41, 224-231.	2.4	14
56	Full Restoration of Brucella-Infected Dendritic Cell Functionality through V β 9V α 2 T Helper Type 1 Crosstalk. <i>PLoS ONE</i> , 2012, 7, e43613.	2.5	13
57	Beyond CAR T cells: Engineered V β 9V α 2 T cells to fight solid tumors. <i>Immunological Reviews</i> , 2020, 298, 117-133.	6.0	9
58	Development of Predictive Value of Urinary Cytokine Profile Induced During Intravesical Bacillus Calmette-Gu \acute{e} rin Instillations for Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e209-e215.	1.9	8
59	The interplay between the duration of TCR and cytokine signaling determines T cell polarization. <i>European Journal of Immunology</i> , 1999, 29, 4092-4101.	2.9	8
60	A Novel HLA-B18 Restricted CD8+ T Cell Epitope Is Efficiently Cross-Presented by Dendritic Cells from Soluble Tumor Antigen. <i>PLoS ONE</i> , 2012, 7, e44707.	2.5	7
61	Combined chemotherapy and allogeneic human V β 9V α 2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo. <i>Oncolmmunology</i> , 2019, 8, e1649971.	4.6	7
62	An X-ray Vision for Phosphoantigen Recognition. <i>Immunity</i> , 2019, 50, 1026-1028.	14.3	7
63	Emerging Challenges of Preclinical Models of Anti-tumor Immunotherapeutic Strategies Utilizing V β 9V α 2 T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 992.	4.8	6
64	Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model. <i>Cancers</i> , 2021, 13, 1256.	3.7	6
65	Synergism and complementarity between human CD1 AND MHC-restricted T cells, two lymphoid subsets directed against distinct antigenic worlds. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 596.	3.0	3
66	ONCOPROTEIN FOS ACTIVATION IN EPITHELIAL-CELLS INDUCES AN EPITHELIOMESENCHYMAL CONVERSION AND CHANGES THE RECEPTOR ENCODED BY THE FGFR-2 MESSENGER-RNA FROM K-SAM TO BEK. <i>Oncology Reports</i> , 1995, 2, 203-7.	2.6	3
67	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells. <i>Clinical Immunology</i> , 2015, 158, 92-99.	3.2	2
68	Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	2
69	V β 9V α 2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e955343.	4.6	1
70	Contribution of the SYK Tyrosine kinase expression to human iNKT self-reactivity. <i>European Journal of Immunology</i> , 2020, 50, 1454-1467.	2.9	1
71	Abstract 3533: Acquisition of antigen presenting cell functions by V β 9V α 2-T cells requires trogocytosis. , .		0
72	Post-Transplant Cyclophosphamide (PTCY) Vs Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) in Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Immune Reconstitution. <i>Blood</i> , 2015, 126, 1955-1955.	1.4	0